Zealand Pharma A/S (OTCMKTS:ZLDPF) Now Covered by Analysts at JPMorgan Chase & Co.

Investment analysts at JPMorgan Chase & Co. assumed coverage on shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) in a report released on Friday, MarketBeat reports. The brokerage set an “overweight” rating on the stock.

Zealand Pharma A/S Stock Performance

Shares of ZLDPF opened at $119.04 on Friday. Zealand Pharma A/S has a one year low of $40.40 and a one year high of $141.74. The stock has a 50-day moving average price of $122.93 and a 200 day moving average price of $115.43. The company has a debt-to-equity ratio of 0.03, a current ratio of 35.57 and a quick ratio of 35.57.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last released its earnings results on Thursday, August 15th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.61) by ($0.06). Zealand Pharma A/S had a negative net margin of 191.92% and a negative return on equity of 18.17%. The business had revenue of $4.93 million for the quarter, compared to analysts’ expectations of $0.50 million. On average, equities analysts forecast that Zealand Pharma A/S will post -2.48 earnings per share for the current fiscal year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.